RITUXIMAB

Brand name:

• Ruxience®

Pharmaceutical company:

Pfizer Australia Pty Ltd

Condition/indication:
(therapeutic use)

• Non-Hodgkin’s lymphoma (NHL); Chronic lymphocytic leukaemia (CLL); Rheumatoid arthritis (RA); Granulomatosis with polyangiitis (Wegener’s granulomatosis) (GPA); Microscopic polyangiitis (MPA).

PBAC Submission type:

New listing (–)

Comment:

--

Public Summary Document:

Public Summary Documents – November 2021

Related medicines:

--

Submission received for:

November 2021 PBAC meeting

Opportunity for consumer comment:

Open 28/07/2021 and close 22/09/2021 (see PBS Website)

PBAC meeting:

Held on 03/11/2021

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

23/02/2022

Lodgement of required documentation:

09/03/2022

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 18/03/2022

Status:

Finalised

Government processes:

Commenced on 01/04/2022

Medicine listed on the PBS:

01/06/2022 (see PBS schedule)

---